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Abstract
Objective—Despite evidence for the validity of premenstrual dysphoric disorder (PMDD) and its 
recent inclusion in DSM-5, variable diagnostic practices compromise the construct validity of the 
diagnosis and threaten the clarity of efforts to understand and treat its underlying pathophysiology. 
In an effort to hasten and streamline the translation of the new DSM-5 criteria for PMDD into 
terms compatible with existing research practices, we present the development and initial 
validation of the Carolina Premenstrual Assessment Scoring System (C-PASS). The C-PASS is a 
standardized scoring system for making DSM-5 PMDD diagnoses using 2 or more menstrual 
cycles of daily symptom ratings using the Daily Record of Severity of Problems (DRSP).
Method—Two hundred women recruited for retrospectively-reported premenstrual emotional 
symptoms provided 2–4 menstrual cycles of daily symptom ratings on the DRSP. Diagnoses were 
made by expert clinician and the C-PASS.
Results—Agreement of C-PASS diagnosis with expert clinical diagnosis was excellent; overall 
correct classification by the C-PASS was estimated at 98%. Consistent with previous evidence, 
retrospective reports of premenstrual symptom increases were a poor predictor of prospective C-
PASS diagnosis.
Conclusions—The C-PASS (available as a worksheet, Excel macro, and SAS macro) is a 
reliable and valid companion protocol to the DRSP that standardizes and streamlines the complex, 
multilevel diagnosis of DSM-5 PMDD. Consistent use of this robust diagnostic method would 
result in more clearly-defined, homogeneous samples of women with PMDD, thereby improving 
the clarity of studies seeking to characterize or treat the underlying pathophysiology of the 
disorder.
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Introduction
Diagnostic Issues in Premenstrual Dysphoric Disorder
Characterized by the emergence of emotional symptoms in the luteal phase of the menstrual 
cycle, Premenstrual Dysphoric Disorder (PMDD) causes severe distress and impairment 
among the estimated 3–8% of women meeting DSM-5 criteria1,2. Another 10–11% of 
women show evidence of a menstrually-related mood disorder (MRMD) causing distress 
and impairment sufficient to warrant treatment despite failure to meet full DSM-5 criteria2. 
Due to the poor prospective validity of retrospectively-reported premenstrual symptoms, 
valid diagnosis requires evaluation of prospective daily symptom ratings3. In research 
settings, diagnosis is often made by visual inspection of daily symptom ratings7 (see Figure 
1, Panel A). However, laboratories differ in the specific manner that daily ratings are 
translated into diagnostic decisions8,9, and the complex, multilevel nature of the diagnosis 
suggests high risk of diagnostician error. These issues motivated development of the 
Carolina Premenstrual Assessment Scoring System (C-PASS), a standardized, computerized 
procedure for the reliable prospective diagnosis of DSM-5 PMDD.
The Complex, Multilevel Diagnosis of PMDD
DSM-5 PMDD is multifaceted and multilevel, requiring many conditions to be met (i.e., 
content, cyclicity, severity, and chronicity) at various levels (i.e., symptoms, cycles, women). 
DSM-5 symptoms and their overlap with the items of the Daily Record of Severity of 
Problems (DRSP)4, the most widely used daily symptom scale, are listed in Table 1. Table 2 
outlines our conceptualization of DSM-5 diagnostic dimensions, including: (1) the content 
dimension, referring to the nature and number of symptoms; five symptoms must be present, 
of which one must be a core emotional symptom, (2) the cyclicity dimension, referring to 
both relative premenstrual elevation (“premenstrual change”) and absolute postmenstrual 
clearance of symptoms, describes the premenstrual onset and postmenstrual offset of 
symptoms in the perimenstrual timeframe5, (3) the clinical significance dimension, 
dictating that symptoms must be of sufficient absolute premenstrual severity and 
premenstrual duration as to cause clinically significant distress or impairment, and (4) the 
chronicity dimension, requiring symptoms to be present in the majority of months.
Translating DSM-5 Dimensions into Standardized Thresholds for the DRSP
The DRSP4 measures all 11 DSM-5 PMDD symptoms. Women rate daily symptoms on a 6-
point scale from 1–Not at all to 6–Extreme. This allows for evaluation of symptom 
dimensions described above; however, DSM-5 does not give numeric thresholds for most 
dimensions, leading to variability in thresholds used across laboratories. Although the field 
has made some strides in standardizing diagnosis6, at least two key inconsistencies remain. 
First, the DSM-5 requirement of “severe” premenstrual symptoms (absolute severity) and 
“minimal or absent” postmenstrual symptoms (absolute clearance) is subjective, and 
different studies set this threshold for clinical significance of symptoms at different ratings 
on the DRSP7. The developers of the DRSP suggest that the most liberal acceptable 
delineation of “clinically significant” symptoms would be at greater than or equal to 4 
(“moderate”)4. In order to reduce the risk of diagnosing normal affective experiences as a 
mental disorder8–10, we recommend that this cutoff of “4-moderate” be implemented 
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consistently as the threshold for absolute severity (premenstrual symptoms must reach 4) 
and absolute symptom clearance (postmenstrual symptoms must not exceed 3). Second, 
although 30% premenstrual elevation (or premenstrual “change”) is generally used5,11 as the 
elevation threshold, at least five different methods have been used to calculate this 
premenstrual change variable (listed in Table 3 note)18,19,20,7,12,13. Therefore, the present 
study begins by examining the interactive effects of both differing calculation methods and 
differing thresholds on diagnostic prevalence.
The Benefits of Computerizing Diagnosis
Even with validated numeric thresholds, many factors may limit the reliability of PMDD 
diagnoses made using visual inspection, making computerized diagnosis preferable. First, 
although it is possible to evaluate many of the diagnostic dimensions by simple visual 
inspection of daily ratings, premenstrual symptom elevation relative to one’s postmenstrual 
(follicular) symptoms—the most discriminating feature of PMDD11—must be calculated for 
each symptom in each cycle. Second, validated numeric criteria have limited clinical utility 
if a clinician must calculate and concatenate the diagnostic dimensions “by hand” at 
symptom, cycle, and person levels across 1700 daily ratings (i.e., 3 months). Third, visual 
inspection of ratings across the entire cycle requires that the diagnostician ignore a great deal 
of distracting information that is not central to the diagnosis of PMDD. Finally, common 
errors of clinical judgment such as the tendency to ignore base rates (which in this case are 
low; 3–8% with PMDD and an additional 10–11% with non-PMDD MRMD2,14) or assign 
too much importance to easily accessible information (e.g., absolute premenstrual symptom 
severity vs. the more complicated relative premenstrual symptom elevation) may introduce 
diagnostic error10–12. Therefore, although valid diagnosis of PMDD is possible using simple 
visual inspection4, poor reliability of such visual diagnosis is likely due to busy clinician 
schedules and sources of unconscious error. It is this state of affairs that motivated our 
development of a computerized approach13 to making the complex diagnosis of PMDD.
Goals of the Carolina Premenstrual Assessment Scoring System (C-PASS)
This paper describes development of the C-PASS in a sample of 200 women seeking 
diagnosis with PMDD. We had four goals. First, by providing this standardized scoring 
system, we aim to promote the reliability—and, by extension, the construct validity—of the 
PMDD diagnosis by eliminating diagnostician variability and error. Given the important 
sociocultural considerations raised around the DSM-5 diagnosis, we feel that a move toward 
diagnostic specificity and reliability is critical8–10. Second, C-PASS data output provides 
dimensional variables for each woman, with the goal of promoting the dimensional (vs. 
categorical) study of premenstrual dysphoria. Third, C-PASS visual output maximizes 
attention to central diagnostic information (see Figure 1, Panel B), with the goal of 
integrating the benefits of visual inspection with the reliability of computerization. Fourth, 
the C-PASS aims to improve the clarity of pathophysiological studies of PMDD by 
permitting more homogeneous clinical samples.
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Methods
Description of the C-PASS Diagnostic Method
The C-PASS SAS Macro, Excel Macro, and worksheet are available at http://
www.toryeisenlohrmoul.com/cpass. The macro code was developed using a double-coding 
technique by authors TAEM and JJ. The diagnostic process begins by characterizing each 
DRSP item in each cycle (where a cycle is defined as a set of contiguous premenstrual and 
postmenstrual weeks from consecutive cycles) using the four diagnostic dimensions as 
described in Table 2 (relative symptom elevation: percent symptom elevation during 
premenstrual week relative to the postmenstrual week >=30%; see Table 3, Method 2; 
absolute clearance: postmenstrual week maximum <=3; absolute severity: premenstrual 
week maximum >=4; and duration: severe premenstrual week days >=2). Because DSM-5 
PMDD is defined as a marked on-off pattern occurring in the perimenstrual timeframe, the 
C-PASS utilizes the premenstrual week (defined as days −7 to −1, where −1 is the day prior 
to menstrual onset) and the postmenstrual week (defined as the 7 days following average 
menstrual offset: days 4 to 10, where day 1 represents menstrual onset). That is, the rationale 
for comparing the premenstrual week of one menstrual cycle to the contiguous 
postmenstrual week of the next cycle is to establish the “switch off” of symptoms, as it is 
critical to demonstrate that the cyclical symptoms do not persist into the follicular phase. 
Further, the C-PASS requires that at least 3 out of 7 ratings be present in each of the two 
weeks, and requires two cycles (i.e., perimenstrual frames).
While the DSM-IV research diagnosis of PMDD required premenstrual impairment, the 
DSM-5 no longer does. Therefore, the interference items on the DRSP are not included in 
the C-PASS, although information about the cyclicity and clinical significance of life 
interference items from the DRSP can be examined as secondary outcomes.
Next, cycle-level diagnosis of PMDD is made by counting DSM-5 symptoms meeting 
criteria on all four dimensions (Table 2; Total Symptoms: 1–4 for MRMD and >=5 for 
PMDD) and whether a core symptom meets criteria (number of core symptoms >=1). Next, 
MRMD or PMDD diagnosis is made at the person level by counting the number of cycles 
meeting MRMD and PMDD criteria (cycles meeting criteria >=2). Finally, the C-PASS 
creates a visual representation of relevant information for each DRSP item across as many 
cycles as provided (see Figure 1, Panel B), along with a determination of cycle-level 
diagnosis for that symptom in each cycle. The system also outputs a dataset with person-
level summary variables for each symptom on each diagnostic dimension. In the present 
study, the more common research diagnosis of MRMD5 (i.e., 1–4 symptoms met for at least 
2 cycles, of which one must be a core emotional symptom) was also calculated. Although 
the C-PASS diagnosis is designed to be made by a computer, a worksheet in the 
supplemental materials allows for manual replication of C-PASS diagnoses.
Participants, Procedure, and Materials
Between 2009–2015, naturally cycling women aged 18–47 (M = 32.70, SD = 8.21) with 
regular cycles (21–35 days) were recruited through flyers and emails seeking women with 
premenstrual emotional symptoms. Women were excluded for chronic medical disorders; 
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histories of mania, substance dependence, or psychosis; any current SCID-I diagnosis; and 
certain medications (antidepressants, benzodiazepines, neuroleptics, or hormonal 
preparations). Participants were not paid. At a baseline visit, participants reported their 
medical and medication history and completed the SCID-I15. Participants retrospectively 
reported the degree of premenstrual increase in each of 21 symptoms16 on a 4-point Likert 
scale from 1–No change to 4–Severe change (α = .91). Two hundred sixty-seven eligible 
women completed prospective assessment.
Prospective assessment included 2–4 cycles of daily DRSP ratings. Participants noted daily 
events they believed to have impacted daily mood; days in which participants reported the 
occurrence of a severe stressor not caused by symptoms were coded as missing. Participants 
mailed in forms weekly. In the final sample, 200 women provided at least two cycles. 
Eighty-five percent of women who dropped out after 1 cycle had not met C-PASS PMDD 
criteria in the first cycle. In women with >= 2 cycles, missing days were minimal (3.4%); 
just 1% of daily data were missing due to external events. Expert diagnoses (coauthor DR) 
of MRMD made prior to the development of the C-PASS (on the basis of identical data) 
were available for the majority of our sample (193 women; 96.5%). Because the DRSP 
summed total score demonstrates inadequate reliability of change17, descriptive statistics for 
single items are considered.
Results
At least five equations are used in the existing literature to calculate relative premenstrual 
symptom elevation, and several thresholds for diagnosis are proposed (30%, 50%, and 75%). 
With [pre-menstrual week average – post-menstrual week average] as the constant 
numerator, the five calculation methods differ in the denominator used: (1) post-menstrual 
average (denominator: postmenstrual week average), varying by cycle, (2), range of scale 
used across all ratings (denominator: woman’s maximum rating-1), varying by woman, (3) 
full scale range (fixed denominator: 5), (4) premenstrual average (denominator: 
premenstrual week average), varying by cycle, and (5) standard deviation (denominator: 
standard deviation of this symptom in this cycle for this woman), varying by symptom and 
cycle. Of note, the standard deviation method utilizes a constant one-standard-deviation 
threshold. In Table 3, we examine the combined impact of these five calculation methods 
and three thresholds on diagnostic prevalence.
Calculation method and threshold used to define significant relative symptom elevation had 
a large impact on diagnostic prevalence (see Table 3). The follicular mean method 
consistently proved to be the most liberal, resulting in much higher average relative 
premenstrual elevation values (p < .0001 for all method-wise comparisons) and the highest 
prevalence rates. The premenstrual mean and standard deviation methods appeared slightly 
more conservative, while the range of scale used and full scale methods appeared most 
conservative. Increasing % thresholds reduced diagnostic prevalence, particularly when 
using full range and range of scale used methods. For the C-PASS protocol, we selected the 
range of scale used method paired with a 30% threshold. This method produced prevalence 
rates consistent with previous epidemiological studies18 assuming that rates of diagnosis 
should be higher in this sample of women seeking to participate in a study of premenstrual 
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affective symptoms. Additionally, this method maximizes generalizability of results to 
women who may not use the full DRSP response scale. In the context of the range of scale 
used method, a threshold of 30% was selected on the basis of highest agreement with expert 
diagnosis (94.3% agreement using the 30% threshold; 34% agreement using 50% threshold, 
12% agreement using the 75% threshold).
Once the protocol was finalized, we used the C-PASS to identify three diagnostic groups 
(No Diagnosis: n=116, 58%; Non-PMDD MRMD: n=46, 23%; DSM-5 PMDD: n=38, 
19%). Table 4 presents descriptive statistics for diagnostic dimensions by group.
Criterion Validity: Comparing C-PASS Diagnosis to Expert Diagnosis
Comparison of CPASS decisions (MRMD vs. no MRMD) to expert diagnosis revealed 
94.3% agreement (11 disagreements). Inspection of ratings and clinical notes revealed three 
reasons for disagreement, each of which are instructive as to either the usefulness of the C-
PASS or ways to improve the C-PASS moving forward.
In four cases, women were diagnosed by the C-PASS that were not diagnosed by expert 
clinician due to persistent background symptoms. Upon inspection of the raw data, the C-
PASS had identified repeating cyclical patterns of anxiety (in 2 women) or interpersonal 
rejection sensitivity and anger (in 2 women). Of note, the DSM-5 does allow PMDD 
diagnosis to be made in such a case, so long as this pattern of symptoms does not represent 
an exacerbation of an underlying mood disorder, which were exclusionary in this study. 
Given (1) the clear evidence of repeating premenstrual elevations and postmenstrual declines 
on these symptoms and (2) the absence of Axis 1 disorder, we believe that the C-PASS 
decision for these women is accurate.
In three additional cases, women with insufficient premenstrual symptom severity 
(symptoms failed to reach a rating of “4–Moderate” in the premenstrual phase) or duration 
(less than two premenstrual days of at least moderate symptoms) were diagnosed with 
MRMD by the visual inspection that were not diagnosed by the C-PASS. Although these 
women showed genuine symptom cyclicity, they fail to meet the a priori definition of a 
mental disorder, and we feel that the C-PASS decision is accurate.
In the remaining four cases, women with “late” menstrual clearance of symptoms 
(symptoms persisting through the end of menses) were accurately diagnosed by expert 
clinician, whereas the C-PASS, which evaluates symptom clearance during days 4 to 10, 
failed to diagnose these women because it judged that symptoms had not cleared adequately. 
We feel that the expert clinician was correct in these cases, and this provides an important 
area for improving the C-PASS. In a future study (for which data collection is underway), 
we will evaluate differences between (1) diagnosis made based on standardized days 4 to 10, 
and (2) diagnosis made based on an individualized last day of menses +7 days. Although the 
latter may seem the intuitive choice, the former may have the benefit of greater biological 
validity, as the start of menstrual bleeding is a less ambiguous stimulus to self-report than 
the end of menses. In sum, we feel that the C-PASS mistakenly failed to diagnose just 4 
women (2% of sample).
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Comparison of Retrospective Premenstrual Symptoms to C-PASS Diagnosis
Consistent with previous reports16, logistic regression revealed that retrospectively-reported 
premenstrual symptom change was a very poor predictor of both C-PASS MRMD diagnosis 
(Standardized B = .038, SE = .011, X2 = 11.46, p = .0007, OR for a 1 SD increase in 
retrospective symptoms = 1.03, 95% CI: 1.01 to 1.06) and C-PASS PMDD diagnosis 
(Standardized B = .061, SE = .016, X2 = 14.01, p = .0002, OR for a 1 SD increase in 
retrospective symptoms = 1.06, 95% CI: 1.03 to 1.09). Given this poor predictive validity of 
retrospectively reported premenstrual symptoms, attempts to identify a reasonably sensitive 
and specific cutoff value for the prediction of C-PASS diagnoses were unsuccessful (AUC 
for MRMD Diagnosis= .63, 95% CI: .56 to .70; AUC for PMDD Diagnosis = .70, 95% CI: .
62 to .78).
Discussion
Despite evidence for the existence and burden of PMDD6, inconsistent diagnostic practices 
compromise the construct validity of PMDD10, undermine accurate clinical diagnosis19, and 
threaten the clarity of efforts to characterize the pathophysiology of the disorder. In an effort 
to hasten and standardize the translation of the DSM-5 PMDD criteria into terms compatible 
with existing research practices, the present paper presents the Carolina Premenstrual 
Assessment Scoring System (C-PASS), a scoring system for prospective ratings on the 
DRSP that can be used either manually or with macro programs for SAS and Excel.
The present paper also draws attention to and resolves an egregious mathematical 
inconsistency in the existing literature: the use of at least five different equations for 
calculating the degree of premenstrual symptom elevation relative to baseline (also referred 
to as “premenstrual change”) has likely introduced unacceptable between-laboratory 
variability in the meaning of MRMD/PMDD across laboratories. In light of the present 
findings, we recommend that the range of scale used method (Table 3) be utilized in 
combination with a 30% threshold. Regardless of methods used, both calculation equations 
and thresholds should always be explicitly described. This represents a crucial step toward 
replicability of findings.
The present work holds the potential to increase the reliability of PMDD diagnosis; however, 
additional work should further examine the validity of the diagnostic thresholds used in the 
C-PASS, especially the number of symptoms per cycle that best defines a group of women in 
need of diagnosis and treatment. Of note, the dimensions of PMDD diagnosis were normally 
distributed; ultimately, PMDD may be best conceptualized in a continuous, dimensional 
manner that could be described more precisely in future iterations of the DSM 
(“unisymptom” vs. “multisymptom”; or “with rapid offset” vs. “with gradual offset”). 
Relatedly, future research must determine whether MRMD and PMDD arise from normally-
distributed risk processes related to those described in the Research Diagnostic Criteria 
(RDoC)20,21 framework, or whether there are more categorical pathophysiological processes 
at play.
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Limitations and Future Directions
Several limitations of this study are noteworthy: First, because the C-PASS is designed to 
identify premenstrual symptoms of a clinically significant nature, it may therefore fail to 
identify women who demonstrate significant menstrual-cycle entrainment of symptoms that 
are not premenstrual (e.g., at midcycle), or those who do not show sufficient absolute 
severity or clearance. Second, because the C-PASS seeks to balance efficiency with 
reliability, it does not consider mid-cycle symptoms; if significant late follicular symptoms 
are present, this may signal the need for differential diagnosis. Third, the C-PASS is 
developed for the DRSP, given that this scale assesses all DSM-5 content; however, other 
useful rating scales for PMDD exist (e.g., the Daily Symptom Record24). Limitations of the 
DRSP, such as scale sensitivity (i.e., relative to a 100mm scale) and unbalanced content 
coverage should be addressed. Fourth, the C-PASS may fail to accurately diagnose some 
women with late symptom clearance; future work should determine whether self-reported 
menstrual offset is sufficiently accurate to permit the use of personalized postmenstrual 
weeks for each woman. Additional validation work must demonstrate that the methods and 
thresholds selected here are calibrated to ensure only the diagnosis of women who need 
treatment. Finally, women seeking treatment for PMDD in clinical settings may prove to be 
qualitatively different from women in research settings.
Research Applications
The C-PASS has myriad applications in research. In the context of clinical research, the use 
of a standardized, reliable system of diagnosis would ensure shared diagnostic meaning 
across laboratories, and would ensure homogenous samples. The C-PASS also allows for 
dimensional characterization of symptoms across samples, individuals, and cycles according 
to four central dimensions of PMDD diagnosis (see Table 2), which may allow for the 
eventual identification of meaningful differences, if any, between women with PMDD and 
other MRMDs. Further development of this system may allow for the identification of 
distinct subgroups with differing pathophysiology22. Finally, it should be noted that the C-
PASS can also be used to identify cycles meeting criteria for PMDD, a feature that could be 
useful for defining treatment response.
Clinical Implications
There are currently no reliable and valid diagnostic procedures for PMDD that are feasible 
for widespread clinical application. Given the time involved in prospective assessment, 
nearly 90% of clinicians who treat PMDD rely on patient retrospective self-report, which we 
know to be prone to false positives, to make diagnoses19. This is troubling when considered 
in tandem with the present evidence that (1) there is a relatively low prevalence of true 
PMDD even among women seeking assessment for premenstrual symptoms, and (2) 
variability on retrospective self-report of premenstrual symptoms does not provide 
information about whether a standardized, prospective diagnosis of PMDD is present. 
Rigorous experimental23 and longitudinal14 studies have established the biological validity 
of PMDD, and treatments are available; however, assessments that combine validity, 
reliability, and efficiency need to be developed so that women with the disorder can receive 
treatment, and women without the disorder can search for alternative causes of their 
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symptoms. Standardization of research diagnoses through the C-PASS represents an initial 
step toward development of efficient and reliable clinical tools. The current C-PASS 
materials may be immediately useful clinically; however, additional development is needed 
to digitize data collection and streamline the diagnostic process for clinical application.
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Acknowledgments
This work was supported by grants from the National Institute of Mental Health (R01MH099076, R01MH081837, 
and T32MH093315).
References
1. Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J 
Psychiatry Neurosci. 2008; 33(4):291–301. [PubMed: 18592027] 
2. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden 
of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003; 28:1–23. 
DOI: 10.1016/S0306-4530(03)00098-2
3. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and 
predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. Journal of 
Affective Disorders. 2002; 70(2):125–132. DOI: 10.1016/S0165-0327(01)00458-X [PubMed: 
12117624] 
4. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and 
validity. Arch Womens Ment Health. 2006; 9(1):41–49. DOI: 10.1007/s00737-005-0103-y 
[PubMed: 16172836] 
5. Halbreich U, Bäckström T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome 
and guidelines for their quantification for research studies. 2009; 23(3):123–130. http://
dxdoiorgezproxyukyedu/101080/09513590601167969. DOI: 10.1080/09513590601167969
6. Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new 
category for DSM-5. American Journal of Psychiatry. 2012; 169(5):465–475. DOI: 10.1176/
appi.ajp.2012.11081302 [PubMed: 22764360] 
7. Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the Criteria Used for Identification of 
PMS. 2006; 15(5):546–555. http://dxdoiorg/101089/jwh200615546. DOI: 10.1089/jwh.2006.15.546
8. Pugliesi K. Premenstrual syndrome: The medicalization of emotion related to conflict and chronic 
role strain. Humboldt Journal of Social Relations. 1992
9. McDaniel SH. The interpersonal politics of premenstrual syndrome. Family Systems Medicine. 
1988; 6(2):134.
10. SA H, CA B, KA Y. Addressing concerns about the inclusion of premenstrual dysphoric disorder 
in DSM-5. The Journal of clinical psychiatry. 2014; 75(1):70–76. DOI: 10.4088/JCP.13cs08368 
[PubMed: 24345853] 
11. Smith MJ, Schmidt PJ, Rubinow DR. Operationalizing DSM-IV criteria for PMDD: selecting 
symptomatic and asymptomatic cycles for research. Journal of Psychiatric Research. 2003; 37(1):
75–83. [PubMed: 12482472] 
12. Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for Premenstrual Dysphoric Disorder: 
Secondary Analyses of Relevant Data Sets. Arch Gen Psychiatry. 2012; 69(3):300–305. DOI: 
10.1001/archgenpsychiatry.2011.1368 [PubMed: 22393222] 
13. Hurt SW, Schnurr PP, Severino SK, et al. Late luteal phase dysphoric disorder in 670 women 
evaluated for premenstrual complaints. American Journal of Psychiatry. 1992; 149(4):525–530. 
[PubMed: 1554039] 
Eisenlohr-Moul et al. Page 9
Am J Psychiatry. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual 
dysphoric disorder in the community. Psychol Med. 2002; 32(1):119–132. [PubMed: 11883723] 
15. First, MB.; Spitzer, RL.; Gibbon, M.; Williams, JBW. User’s Guide for the Structured Clinical 
Interview for DSM-IV Axis I Disorders SCID-I. American Psychiatric; 1997. 
16. Endicott J, Halbreich U. Retrospective Report of Premenstrual Depressive Changes: Factors 
Affecting Confirmation by Daily Ratings. Psychopharmacol Bull. 1982
17. Eisenlohr-Moul TA, Rubinow DR, Schiller CE. Histories of abuse predict stronger within-person 
covariation of ovarian steroids and mood symptoms in women with menstrually related mood 
disorder. Psychoneuroendocinology. 2016 In press. 
18. Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual Dysphoric Disorder: Evidence for a 
New Category for DSM-5. American Journal of Psychiatry. 2012; 169(5):465–475. DOI: 10.1176/
appi.ajp.2012.11081302 [PubMed: 22764360] 
19. Craner JR, Sigmon ST, McGillicuddy ML. Does a disconnect occur between research and practice 
for premenstrual dysphoric disorder (PMDD) diagnostic procedures? Women & Health. 2014; 
54(3):232–244. DOI: 10.1080/03630242.2014.883658 [PubMed: 24512469] 
20. Etkin A, Cuthbert B. Beyond the DSM: Development of a Transdiagnostic Psychiatric 
Neuroscience Course. Acad Psychiatry. 2014; 38(2):145–150. DOI: 10.1007/s40596-013-0032-4 
[PubMed: 24493358] 
21. Cuthbert B, Insel T. Classification issues in women’s mental health: clinical utility and etiological 
mechanisms. Arch Womens Ment Health. 2010; 13(1):57–59. DOI: 10.1007/s00737-009-0132-z 
[PubMed: 20058041] 
22. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. 
Psychoneuroendocrinology. 2003; 28:55–99. DOI: 10.1016/S0306-4530(03)00097-0
23. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects 
of gonadal steroids in women with and in those without premenstrual syndrome. The New England 
journal of medicine. 1998; 338(4):209–216. [PubMed: 9435325] 
Eisenlohr-Moul et al. Page 10
Am J Psychiatry. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Typical Visualization of DRSP Daily Symptom Ratings Across Two Cycles (Panel A) vs. C-
PASS Visualization of DRSP Daily Symptom Ratings Across Three Cycles (produced by the 
SAS C-PASS Macro; Panel B)
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Table 1
Mapping the Items of the DRSP onto DSM-5 Diagnostic Content
DRSP ITEMS DSM-5 PMDD CONTENT
CORE SYMPTOMS/CRITERION B
DRSP 5. Had mood swings (e.g. suddenly felt sad or 
tearful) 1. Marked affective lability (e.g., mood swings; feeling suddenly sad or tearful, or 
increased sensitivity to rejection)DRSP 6. Was more sensitive to rejection or my feelings 
were easily hurt
DRSP 7. Felt angry, irritable
2. Marked irritability or anger or increased interpersonal conflicts
DRSP 8. Had conflicts or problems with people
DRSP 1. Felt depressed, sad, “down” or blue
3. Marked depressed mood, feelings of hopelessness, or self-deprecating thoughtsDRSP 2. Felt hopeless
DRSP 3. Felt worthless or guilty
DRSP 4. Felt anxious, “keyed up”, or “on edge” 4. Marked anxiety, tension, and/or feelings of being keyed up or on edge
ADDITIONAL SYMPTOMS/CRITERION C
DRSP 9. Had less interest in usual activities (e.g. work, 
school, friends, hobbies) 1. Decreased interest in usual activities (e.g. work, school, friends, hobbies)
DRSP 10. Had difficulty concentrating 2. Subjective difficulty in concentration
DRSP 11. Felt lethargic tired, fatigued, or had a lack of 
energy 3. Lethargy, easy fatigability, or marked lack of energy
DRSP 12. Had increased appetite or overate
4. Marked change in appetite; overeating; or specific food cravings
DRSP 13. Had specific food cravings
DRSP 14. Slept more, took naps, found it hard to get 
up 5. Hypersomnia or Insomnia
DRSP 15. Had trouble getting to sleep, staying asleep
DRSP 16. Felt overwhelmed, that I couldn’t cope
6. A sense of being overwhelmed or out of control
DRSP 17. Felt out of control
DRSP 18. Had breast tenderness
7. Physical symptoms such as breast tenderness or swelling, joint or muscle pain, 
sensation of “bloating”, or weight gain
DRSP 19. Had breast swelling, felt bloated, or had 
weight gain
DRSP 21. Had Joint or muscle pain
DRSP 20. Had headache
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Table 2
Diagnostic Dimensions of DSM-5 Premenstrual Dysphoric Disorder
DIAGNOSTIC DIMENSIONS Diagnosis Based on DRSP DSM-5
Content
Symptoms
Core symptoms:
felt depressed/sad/down/blue, felt hopeless, felt 
worthless/guilty, felt anxious/keyed up/on edge, 
had mood swings, was more sensitive to 
rejection/feelings were easily hurt, felt angry/
irritable, had conflicts/problems with other 
people
Secondary symptoms:
less interest in usual activities, difficulty 
concentrating, lethargic/fatigue/tired/lack of 
energy, increased appetite/overate, specific food 
cravings, slept more/took naps/hard to get up, 
trouble getting to sleep/staying asleep, felt 
overwhelmed/couldn’t cope, felt out of control, 
breast tenderness, breast swelling/felt bloated/
weight gain, headache, joint or muscle pain
Impairment symptoms:
“Less productivity at work, school, home or in 
daily routine”
“Interference with hobbies or social activities 
(avoid, do less)”
“Interference with relationships”
Criterion B:
affective lability, 
irritability/anger/
increased interpersonal 
conflicts, depressed 
mood/feelings of 
hopelessness/self-
deprecating thoughts, 
anxiety/tension/feelings 
of being keyed up/on 
edge
Criterion C:
decreased interest, 
difficulty in 
concentration, lethargy/
easy fatigability/lack of 
energy, change in 
appetite, hypersomnia/
insomnia, 
overwhelmed/out of 
control, physical 
symptoms (breast 
tenderness, muscle pain, 
bloating, weight gain)
Number
  NON-PMDD 
MRMD
≥ 1 core symptom
  PMDD
≥ 1 core symptom
≥ 5 total symptoms
Criterion A:
A total of 5 [at least (one 
or more) of each 
subgroup]
Cyclicity
Relative Premenstrual Elevation
30% (relative to range of scale used) decrease 
from pre-menstrual week (days −7 → −1) to 
postmenstrual week (days 4 → 10) where −1 is 
the day prior to menstrual onse and 1 is 
menstrual onset
Criterion A:
“…present in the week 
before menses…improve 
within a few days after 
the onset of menses”
Absolute Postmenstrual Clearance
Symptoms must not exceed a value of 3 on any 
day during days 4 → 10
Criterion A:
“minimal or absent in 
the week postmenses”
Postmenses = following 
menstrual onset
Clinical Significance
Absolute Premenstrual Severity
4 or more (on a Likert-scale from 1 to 6) Criterion D:
“symptoms are 
associated with 
clinically significant 
distress OR interference 
with work, school, usual 
social activities, or 
relationships with 
others”
Premenstrual Duration
At least 2 days (doesn’t have to be consecutive) Criterion D:
“in the final week before 
the onset of menses”
Not Simply Cyclicity of Other Disorder
Rule out dysmenorrhea using prospective 
ratings.
Rule out mood and anxiety disorder with 
SCID-1.
Rule out Borderline Personality Disorder with 
SCID-2.
Criterion E:
“not merely an 
exacerbation of the 
symptoms of another 
disorder.”
“Key differential 
diagnoses: 
dysmenorrhea, bipolar 
disorder, MDD, 
dysthymia, and BPD.”
Chronicity ≥ 2 symptomatic months Criterion A and F:
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DIAGNOSTIC DIMENSIONS Diagnosis Based on DRSP DSM-5
“In the majority of 
menstrual cycles…”
“…should be confirmed 
by prospective daily 
ratings during at least 
two symptomatic 
cycles.”
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